Smilow Cancer Hospital Gastrointestinal Cancers Program
Smilow Cancer Hospital at North Haven
6 Devine Street, Fl 1
North Haven, CT 06473
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 1North Haven, CT 06473
Stacey Stein, MD
Gastrointestinal Oncology, Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Medical Oncology and Internal Medicine
Biography
Stacey Stein, MD, specializes in medical oncology with a focus on liver and gallbladder cancers, specifically hepatocellular carcinoma, intrahepatic bile duct cancer, and gallbladder neuroendocrine tumors. She is the assistant medical director of the clinical trials office.
Dr. Stein cares for patients with advanced liver disease. She helps to educate her patients and their families about their liver disease. Her interests include chemotherapy, radiotherapy, immunotherapy, biomarkers, precision medicine, gastrointestinal and esophageal cancers, and pancreatic cancer.
Dr. Stein is an associate professor of internal medicine at Yale School of Medicine.
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Assistant Medical Director, Clinical Trials Office
Education & Training
- MDUniversity of Medicine and Dentistry of New Jersey (2004)
- MMSUniversity of Medicine and Dentistry of New Jersey (2000)
- ResidencyMontefiore Medical Center
- FellowshipNew York University Medical Center
Additional Information
Publications
- Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.
- Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky J, Canosa S, Sklar J, Swisher E, Radke M, Ivy P, Boerner S, Durecki D, Hsu C, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British Journal Of Cancer 2023, 130: 476-482. PMID: 38135713, PMCID: PMC10844282, DOI: 10.1038/s41416-023-02534-1.
- Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
- Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
- Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- Stein S. Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions 2021, 05: 277-282. DOI: 10.1055/s-0041-1722932.
- He A, Kim A, Toskich B, Mody K, Kim K, Stein S, Goyal L, Abrams T, Brown D, Goff L, Kim R, Parikh N, Sandow T, Johnson D, Iyer R, Petroziello M, Krishnamurthi S, Martin C, Jiang Y, Akhter N. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2021, 39: tps358-tps358. DOI: 10.1200/jco.2021.39.3_suppl.tps358.
- Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Uhlig J, Stein S, Kim H. P-324 Advanced hepatocellular cancer: Current systemic treatment sequencing and outcomes in the United States. Annals Of Oncology 2020, 31: s195. DOI: 10.1016/j.annonc.2020.04.406.
- Uhlig J, Stein S, Kim K. PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States. Journal Of Clinical Oncology 2020, 38: e16647-e16647. DOI: 10.1200/jco.2020.38.15_suppl.e16647.
- Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: e16052-e16052. DOI: 10.1200/jco.2020.38.15_suppl.e16052.
- Uhlig J, Nie J, Stein S, Cha C, Kim K. 3:09 PM Abstract No. 33 Comparison of radiofrequency ablation and stereotactic radiotherapy for primary treatment of intrahepatic cholangiocellular carcinoma: results from the National Cancer Database. Journal Of Vascular And Interventional Radiology 2020, 31: s19. DOI: 10.1016/j.jvir.2019.12.055.
- Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.
- Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Naik G, Sirard C, Kagey M, Chaney M, Strickler J. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. Journal Of Clinical Oncology 2020, 38: 357-357. DOI: 10.1200/jco.2020.38.4_suppl.357.
- Stein S, Snider J, McCusker M, Miksad R, Alexander B, Castellanos E, Backenroth D, Schrock A, Madison R, Carson K, Ali S. Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts). Journal Of Clinical Oncology 2020, 38: 310-310. DOI: 10.1200/jco.2020.38.4_suppl.310.
- Hsu C, Lee M, Lee K, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Huang C, He R, Ryoo B. LBA7 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: ix187. DOI: 10.1093/annonc/mdz446.006.
- Lee M, Ryoo B, Hsu C, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Abdullah H, He R, Lee K. LBA39 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: v875. DOI: 10.1093/annonc/mdz394.030.
- Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.
- Kamp W, Sellers C, Stein S, Lim J, Kim H. 03:36 PM Abstract No. 320 Survival analysis of patients with hepatitis c and hepatocellular carcinoma receiving interventional oncology therapies and direct-acting antivirals with 12-week sustained viral response. Journal Of Vascular And Interventional Radiology 2019, 30: s141-s142. DOI: 10.1016/j.jvir.2018.12.388.
- Kamp W, Sellers C, Stein S, Lim J, Kim H. Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma. Journal Of Clinical Oncology 2019, 37: 397-397. DOI: 10.1200/jco.2019.37.4_suppl.397.
- Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Lee K, Hsu C, Lee M, Ryoo B, Verret W, He A, Kwan A, Liu B, Iizuka K, Stein S. 150O Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study. Annals Of Oncology 2018, 29: ix47. DOI: 10.1093/annonc/mdy432.002.
- Pishvaian M, Lee M, Ryoo B, Stein S, Lee K, Verret W, Spahn J, Shao H, Liu B, Iizuka K, Hsu C. LBA26 Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Annals Of Oncology 2018, 29: viii718-viii719. DOI: 10.1093/annonc/mdy424.028.
- Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Sirard C, Newman W, Kagey M, Schlienger K, Strickler J. 660P Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. Annals Of Oncology 2018, 29: viii222. DOI: 10.1093/annonc/mdy282.044.
- Kim H, Uhlig J, Stein S, Jill L, Fuchs C. 572P Socioeconomic discrepancies in survival of stage IV colorectal cancer. Annals Of Oncology 2018, 29: viii191. DOI: 10.1093/annonc/mdy281.118.
- Uhlig J, Stein S, Lacy J, Fuchs C, Kim H. 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation. Annals Of Oncology 2018, 29: viii177. DOI: 10.1093/annonc/mdy281.075.
- Johung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.
- Deshpande H, Stein S. Establishment of a medical student elective on the oncology consult service using the seven principles of teaching. Journal Of Clinical Oncology 2018, 36: tps11021-tps11021. DOI: 10.1200/jco.2018.36.15_suppl.tps11021.
- Uhlig J, Sellers C, Stein S, Lacy J, "Kevin" Kim H. Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database. Journal Of Clinical Oncology 2018, 36: e16150-e16150. DOI: 10.1200/jco.2018.36.15_suppl.e16150.
- Stein S, Uboha N, Dooley K, Hochster H. A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis. Journal Of Clinical Oncology 2018, 36: e15555-e15555. DOI: 10.1200/jco.2018.36.15_suppl.e15555.
- Stein S, Pishvaian M, Lee M, Lee K, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K, Ryoo B. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2018, 36: 4074-4074. DOI: 10.1200/jco.2018.36.15_suppl.4074.
- Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinoma. Journal Of Vascular And Interventional Radiology 2018, 29: s139. DOI: 10.1016/j.jvir.2018.01.359.
- Ghodadra A, Raja J, Stein S, Lacy J, Kim H. 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population study. Journal Of Vascular And Interventional Radiology 2018, 29: s113. DOI: 10.1016/j.jvir.2018.01.292.
- Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.
- Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma. Journal Of Clinical Oncology 2018, 36: 465-465. DOI: 10.1200/jco.2018.36.4_suppl.465.
- Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC). Journal Of Clinical Oncology 2017, 35: 4075-4075. DOI: 10.1200/jco.2017.35.15_suppl.4075.
- Kim R, McDonough S, El-Khoueiry A, Bekaii-Saab T, Stein S, Sahai V, Keogh G, Kim E, Baron A, Siegel A, Barzi A, Guthrie K, Javle M, Hochster H. SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Journal Of Clinical Oncology 2017, 35: 4016-4016. DOI: 10.1200/jco.2017.35.15_suppl.4016.
- Goff L, Azad N, Stein S, Whisenant J, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso P, El-Rifai W, Berlin J. Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2017, 35: 2593-2593. DOI: 10.1200/jco.2017.35.15_suppl.2593.
- Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. 698P Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Annals Of Oncology 2016, 27: vi235. DOI: 10.1093/annonc/mdw371.90.
- Ryan D, Murphy J, Mahalingam D, Strickler J, Stein S, Sirard C, Landau S, Bendell J. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals Of Oncology 2016, 27: ii108. PMCID: PMC4984164, DOI: 10.1093/annonc/mdw200.16.
- Eads J, Goyal L, Stein S, El-Khoueiry A, Manji G, Abrams T, Landau S, Sirard C. Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer. Journal Of Clinical Oncology 2016, 34: e15603-e15603. DOI: 10.1200/jco.2016.34.15_suppl.e15603.
- Stein S, James E, Cong X, Deng Y, Salem R, Cha C, Chang B, Hochster H, Doddamane I, Boustani A, Patel V, Kortmansky J, Li J, Staugaard C, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Journal Of Clinical Oncology 2016, 34: 395-395. DOI: 10.1200/jco.2016.34.4_suppl.395.
- Stein S, Cong X, Yao X, Hahn C, Li J, Kortmansky J, Chang B, Cha C, Salem R, Hochster H, Lacy J. Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2015, 33: e15274-e15274. DOI: 10.1200/jco.2015.33.15_suppl.e15274.
- James E, Cong X, Yao X, Hahn C, Kaley K, Li J, Kortmansky J, Fischbach N, Cha C, Salem R, Stein S, Hochster H, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2015, 33: 395-395. DOI: 10.1200/jco.2015.33.3_suppl.395.
- James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.
- James E, Narayan A, Carriero N, Chang B, Lacy J, Stein S, Hochster H, Patel A. Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 3645-3645. DOI: 10.1200/jco.2014.32.15_suppl.3645.
- Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Zhang Y, Hochster H, Stein S, Lacy J. Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. Journal Of Clinical Oncology 2014, 32: 344-344. DOI: 10.1200/jco.2014.32.3_suppl.344.
- James E, Narayan A, Stein S, Lacy J, Patel A, Hochster H. Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 217-217. DOI: 10.1200/jco.2014.32.3_suppl.217.
- James E, Yao X, Cong X, Stein S, Kaley K, Hahn C, Cha C, Salem R, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: 256-256. DOI: 10.1200/jco.2014.32.3_suppl.256.
- Li J, Kortmansky J, Fischbach N, Stein S, Yao X, Hochster H, Lacy J. Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC). Journal Of Clinical Oncology 2013, 31: 4084-4084. DOI: 10.1200/jco.2013.31.15_suppl.4084.
- Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.
- Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Hahn C, Kaley K, Lacy J. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: 330-330. DOI: 10.1200/jco.2012.30.4_suppl.330.
- Singh J, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi H, Davis S, Goldberg J, Tiersten A. P1-17-07: Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer. Cancer Research 2011, 71: p1-17-07-p1-17-07. DOI: 10.1158/0008-5472.sabcs11-p1-17-07.
- Stein S, Hochster H, Muggia F, Blank S, Curtin J, Shapira I, Goldberg G, Tiersten A. Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204). Journal Of Clinical Oncology 2010, 28: 5092-5092. DOI: 10.1200/jco.2010.28.15_suppl.5092.
Locations
Smilow Cancer Hospital Gastrointestinal Cancers Program
Smilow Cancer Hospital at North Haven
6 Devine Street, Fl 1
North Haven, CT 06473
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 1North Haven, CT 06473
Biography
Stacey Stein, MD, specializes in medical oncology with a focus on liver and gallbladder cancers, specifically hepatocellular carcinoma, intrahepatic bile duct cancer, and gallbladder neuroendocrine tumors. She is the assistant medical director of the clinical trials office.
Dr. Stein cares for patients with advanced liver disease. She helps to educate her patients and their families about their liver disease. Her interests include chemotherapy, radiotherapy, immunotherapy, biomarkers, precision medicine, gastrointestinal and esophageal cancers, and pancreatic cancer.
Dr. Stein is an associate professor of internal medicine at Yale School of Medicine.
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Assistant Medical Director, Clinical Trials Office
Education & Training
- MDUniversity of Medicine and Dentistry of New Jersey (2004)
- MMSUniversity of Medicine and Dentistry of New Jersey (2000)
- ResidencyMontefiore Medical Center
- FellowshipNew York University Medical Center
Additional Information
Publications
- Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.
- Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky J, Canosa S, Sklar J, Swisher E, Radke M, Ivy P, Boerner S, Durecki D, Hsu C, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British Journal Of Cancer 2023, 130: 476-482. PMID: 38135713, PMCID: PMC10844282, DOI: 10.1038/s41416-023-02534-1.
- Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
- Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
- Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- Stein S. Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions 2021, 05: 277-282. DOI: 10.1055/s-0041-1722932.
- He A, Kim A, Toskich B, Mody K, Kim K, Stein S, Goyal L, Abrams T, Brown D, Goff L, Kim R, Parikh N, Sandow T, Johnson D, Iyer R, Petroziello M, Krishnamurthi S, Martin C, Jiang Y, Akhter N. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2021, 39: tps358-tps358. DOI: 10.1200/jco.2021.39.3_suppl.tps358.
- Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Uhlig J, Stein S, Kim H. P-324 Advanced hepatocellular cancer: Current systemic treatment sequencing and outcomes in the United States. Annals Of Oncology 2020, 31: s195. DOI: 10.1016/j.annonc.2020.04.406.
- Uhlig J, Stein S, Kim K. PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States. Journal Of Clinical Oncology 2020, 38: e16647-e16647. DOI: 10.1200/jco.2020.38.15_suppl.e16647.
- Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: e16052-e16052. DOI: 10.1200/jco.2020.38.15_suppl.e16052.
- Uhlig J, Nie J, Stein S, Cha C, Kim K. 3:09 PM Abstract No. 33 Comparison of radiofrequency ablation and stereotactic radiotherapy for primary treatment of intrahepatic cholangiocellular carcinoma: results from the National Cancer Database. Journal Of Vascular And Interventional Radiology 2020, 31: s19. DOI: 10.1016/j.jvir.2019.12.055.
- Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.
- Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Naik G, Sirard C, Kagey M, Chaney M, Strickler J. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. Journal Of Clinical Oncology 2020, 38: 357-357. DOI: 10.1200/jco.2020.38.4_suppl.357.
- Stein S, Snider J, McCusker M, Miksad R, Alexander B, Castellanos E, Backenroth D, Schrock A, Madison R, Carson K, Ali S. Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts). Journal Of Clinical Oncology 2020, 38: 310-310. DOI: 10.1200/jco.2020.38.4_suppl.310.
- Hsu C, Lee M, Lee K, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Huang C, He R, Ryoo B. LBA7 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: ix187. DOI: 10.1093/annonc/mdz446.006.
- Lee M, Ryoo B, Hsu C, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Abdullah H, He R, Lee K. LBA39 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: v875. DOI: 10.1093/annonc/mdz394.030.
- Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.
- Kamp W, Sellers C, Stein S, Lim J, Kim H. 03:36 PM Abstract No. 320 Survival analysis of patients with hepatitis c and hepatocellular carcinoma receiving interventional oncology therapies and direct-acting antivirals with 12-week sustained viral response. Journal Of Vascular And Interventional Radiology 2019, 30: s141-s142. DOI: 10.1016/j.jvir.2018.12.388.
- Kamp W, Sellers C, Stein S, Lim J, Kim H. Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma. Journal Of Clinical Oncology 2019, 37: 397-397. DOI: 10.1200/jco.2019.37.4_suppl.397.
- Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Lee K, Hsu C, Lee M, Ryoo B, Verret W, He A, Kwan A, Liu B, Iizuka K, Stein S. 150O Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study. Annals Of Oncology 2018, 29: ix47. DOI: 10.1093/annonc/mdy432.002.
- Pishvaian M, Lee M, Ryoo B, Stein S, Lee K, Verret W, Spahn J, Shao H, Liu B, Iizuka K, Hsu C. LBA26 Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Annals Of Oncology 2018, 29: viii718-viii719. DOI: 10.1093/annonc/mdy424.028.
- Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Sirard C, Newman W, Kagey M, Schlienger K, Strickler J. 660P Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies. Annals Of Oncology 2018, 29: viii222. DOI: 10.1093/annonc/mdy282.044.
- Kim H, Uhlig J, Stein S, Jill L, Fuchs C. 572P Socioeconomic discrepancies in survival of stage IV colorectal cancer. Annals Of Oncology 2018, 29: viii191. DOI: 10.1093/annonc/mdy281.118.
- Uhlig J, Stein S, Lacy J, Fuchs C, Kim H. 529P Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation. Annals Of Oncology 2018, 29: viii177. DOI: 10.1093/annonc/mdy281.075.
- Johung K, Kann B, Lacy J, Stein S, Kortmansky J, Zaheer W, Cheng Y, Lam W, Liu S, Decker R, Hochster H, Higgins S. P-320 Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Annals Of Oncology 2018, 29: v90. DOI: 10.1093/annonc/mdy151.319.
- Deshpande H, Stein S. Establishment of a medical student elective on the oncology consult service using the seven principles of teaching. Journal Of Clinical Oncology 2018, 36: tps11021-tps11021. DOI: 10.1200/jco.2018.36.15_suppl.tps11021.
- Uhlig J, Sellers C, Stein S, Lacy J, "Kevin" Kim H. Combination of local ablation and chemotherapy for intrahepatic cholangiocarcinoma: Survival trends from the National Cancer Database. Journal Of Clinical Oncology 2018, 36: e16150-e16150. DOI: 10.1200/jco.2018.36.15_suppl.e16150.
- Stein S, Uboha N, Dooley K, Hochster H. A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis. Journal Of Clinical Oncology 2018, 36: e15555-e15555. DOI: 10.1200/jco.2018.36.15_suppl.e15555.
- Stein S, Pishvaian M, Lee M, Lee K, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K, Ryoo B. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2018, 36: 4074-4074. DOI: 10.1200/jco.2018.36.15_suppl.4074.
- Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. 3:09 PM Abstract No. 323 Locoregional therapy and systemic chemotherapy versus systemic chemotherapy on outcome for intrahepatic cholangiocarcinoma. Journal Of Vascular And Interventional Radiology 2018, 29: s139. DOI: 10.1016/j.jvir.2018.01.359.
- Ghodadra A, Raja J, Stein S, Lacy J, Kim H. 3:00 PM Abstract No. 261 Radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER-Medicare population study. Journal Of Vascular And Interventional Radiology 2018, 29: s113. DOI: 10.1016/j.jvir.2018.01.292.
- Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.
- Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma. Journal Of Clinical Oncology 2018, 36: 465-465. DOI: 10.1200/jco.2018.36.4_suppl.465.
- Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC). Journal Of Clinical Oncology 2017, 35: 4075-4075. DOI: 10.1200/jco.2017.35.15_suppl.4075.
- Kim R, McDonough S, El-Khoueiry A, Bekaii-Saab T, Stein S, Sahai V, Keogh G, Kim E, Baron A, Siegel A, Barzi A, Guthrie K, Javle M, Hochster H. SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Journal Of Clinical Oncology 2017, 35: 4016-4016. DOI: 10.1200/jco.2017.35.15_suppl.4016.
- Goff L, Azad N, Stein S, Whisenant J, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso P, El-Rifai W, Berlin J. Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2017, 35: 2593-2593. DOI: 10.1200/jco.2017.35.15_suppl.2593.
- Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. 698P Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Annals Of Oncology 2016, 27: vi235. DOI: 10.1093/annonc/mdw371.90.
- Ryan D, Murphy J, Mahalingam D, Strickler J, Stein S, Sirard C, Landau S, Bendell J. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals Of Oncology 2016, 27: ii108. PMCID: PMC4984164, DOI: 10.1093/annonc/mdw200.16.
- Eads J, Goyal L, Stein S, El-Khoueiry A, Manji G, Abrams T, Landau S, Sirard C. Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer. Journal Of Clinical Oncology 2016, 34: e15603-e15603. DOI: 10.1200/jco.2016.34.15_suppl.e15603.
- Stein S, James E, Cong X, Deng Y, Salem R, Cha C, Chang B, Hochster H, Doddamane I, Boustani A, Patel V, Kortmansky J, Li J, Staugaard C, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Journal Of Clinical Oncology 2016, 34: 395-395. DOI: 10.1200/jco.2016.34.4_suppl.395.
- Stein S, Cong X, Yao X, Hahn C, Li J, Kortmansky J, Chang B, Cha C, Salem R, Hochster H, Lacy J. Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2015, 33: e15274-e15274. DOI: 10.1200/jco.2015.33.15_suppl.e15274.
- James E, Cong X, Yao X, Hahn C, Kaley K, Li J, Kortmansky J, Fischbach N, Cha C, Salem R, Stein S, Hochster H, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2015, 33: 395-395. DOI: 10.1200/jco.2015.33.3_suppl.395.
- James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.
- James E, Narayan A, Carriero N, Chang B, Lacy J, Stein S, Hochster H, Patel A. Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 3645-3645. DOI: 10.1200/jco.2014.32.15_suppl.3645.
- Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Zhang Y, Hochster H, Stein S, Lacy J. Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. Journal Of Clinical Oncology 2014, 32: 344-344. DOI: 10.1200/jco.2014.32.3_suppl.344.
- James E, Narayan A, Stein S, Lacy J, Patel A, Hochster H. Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 217-217. DOI: 10.1200/jco.2014.32.3_suppl.217.
- James E, Yao X, Cong X, Stein S, Kaley K, Hahn C, Cha C, Salem R, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: 256-256. DOI: 10.1200/jco.2014.32.3_suppl.256.
- Li J, Kortmansky J, Fischbach N, Stein S, Yao X, Hochster H, Lacy J. Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC). Journal Of Clinical Oncology 2013, 31: 4084-4084. DOI: 10.1200/jco.2013.31.15_suppl.4084.
- Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.
- Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Hahn C, Kaley K, Lacy J. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: 330-330. DOI: 10.1200/jco.2012.30.4_suppl.330.
- Singh J, Stein S, Volm M, Smith J, Novik Y, Speyer J, Adams S, Meyers M, Muggia F, Schneider R, Formenti S, Omene C, Choi H, Davis S, Goldberg J, Tiersten A. P1-17-07: Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer. Cancer Research 2011, 71: p1-17-07-p1-17-07. DOI: 10.1158/0008-5472.sabcs11-p1-17-07.
- Stein S, Hochster H, Muggia F, Blank S, Curtin J, Shapira I, Goldberg G, Tiersten A. Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204). Journal Of Clinical Oncology 2010, 28: 5092-5092. DOI: 10.1200/jco.2010.28.15_suppl.5092.
Locations
Smilow Cancer Hospital Gastrointestinal Cancers Program
Smilow Cancer Hospital at North Haven
6 Devine Street, Fl 1
North Haven, CT 06473
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 1North Haven, CT 06473
Smilow Cancer Hospital Gastrointestinal Cancers Program
Smilow Cancer Hospital at North Haven
6 Devine Street, Fl 1
North Haven, CT 06473
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital at North Haven6 Devine Street, Fl 1North Haven, CT 06473